JPRN-UMIN000023968
Completed
未知
n-blinded Multicenter Study to Assess the Safety of Robotic-assisted (da Vinci surgical system, DVSS) Laparoscopic Partial Nephrectomy for Hilar Tumors - Un-blinded Multicenter Study to Assess the Safety of RAPN for Hilar Tumors
Kobe University Graduate School of Medicine0 sites100 target enrollmentSeptember 20, 2016
ConditionscT1,cN0,cM0 Hilar Tumors
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- cT1,cN0,cM0 Hilar Tumors
- Sponsor
- Kobe University Graduate School of Medicine
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)multiple cancer 2\)history of kidney transplantation. 3\)therapies for renal cell cancer in the past 6 months. 4\) Has a high risk to general anesthesia 5\) unable to withdrawal of anticoagulation 6\) anemia or hemorrhagic tendency requiring transfusion 7\) obesity(Body Mass Index:BMI\>\=35\) 8\) dialysis patient. 9\) pregnant, suspected of being pregnant, or lactating woman. 10\) difficult to participate the study due to psychiatric disorder or psychological symptom. 11 )Judged as an inappropriate patient by the investigator or sub\-investigator at the hospital (site) for any other reasons.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
n-blinded Multicenter Study to Assess the Safety of RAPN for Hilar TumorscT1,cN0,cM0 Hilar TumorsJPRN-jRCT1052190005Masato Fujisawa108
Active, not recruiting
Not Applicable
n-blinded Multicenter Study of Robotic-assisted Laparoscopic Partial NephrectomycT1 Renal CancerJPRN-jRCT1052190004Masato Fujisawa100
Completed
Not Applicable
Multicenter Clinical Study Evaluating the Safety and Efficacy of Dasatinib Treatment and its Discontinuation in Patients with Chronic Phase Chronic Myelogenous Leukemia who had Reached Complete Molecular Response during Imatinib TherapyChronic Phase Chronic Myelogenous LeukemiaJPRN-UMIN000007221Juntendo University School of Medicine40
Completed
Phase 2
A Multi-Centre Clinical Study to Evaluate the Safety and Effectiveness of the ESS505® Device to Prevent Pregnancy in Women Who Are Seeking Permanent ContraceptioWomen ages range 21 to 44 years desiring permanent contraceptionbirth controlcontraceptionNL-OMON39616Bayer40
Active, not recruiting
Phase 1
Safety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fractioHeart failure with reduced ejection fractionMedDRA version: 17.1Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2014-001971-30-ITovartis Farma SPA5,000